An interventional study of Continuous Glucose Monitoring and Point-of-Care Testing in Acute Ischemic Stroke, Diabetes (DM) and Diabetes Type 2, sponsored by Isala. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Isala · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Ischemic Stroke with a site in Netherlands — 14 open to participants now, 17 under way, 2 of them phase 3. Ischemic Stroke · Netherlands.
Among the 45 studies in Ischemic Stroke with a site in Netherlands, this one is the 25th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 13 with no phase, reaches primary completion later than 10 of the 16 other live ones, and was the 44th registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →14 of the 45 studies in Ischemic Stroke with a site in Netherlands are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Netherlands, Belgium, Germany and 3 more countries
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
St. Antonius Hospital · Sites in Netherlands
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Netherlands, Austria, Belgium and 9 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 3
First in 2000; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is below the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 447 across the 34 interventional studies, 300 across the 11 observational. Of the 26 that completed or were terminated, 8 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 45 have an industry lead sponsor. The 10 most frequent:
Isala is the lead sponsor of 36 studies on the registry; 10 are open to participants now.
Isala has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies in Ischemic Stroke with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06871969Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Clinical Evaluation of EEG Device for the Triage of Stroke Patients in the Ambulance | 2026-12 |
| NCT05853796Radboud University Medical CenterObservational Dutch Young Symptomatic StrokE studY - nEXT | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 45 studies in Ischemic Stroke with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomized clinical trial is to evaluate whether continuous glucose monitoring (CGM) can be used to guide glucose management in patients with type 2 diabetes who are admitted with an acute ischemic stroke and undergo endovascular therapy. Hyperglycemia frequently occurs during hospitalization in stroke and is associated with worse neurological and clinical outcomes. In current clinical practice, glucose levels are monitored using intermittent point-of-care testing (POCT) with finger-prick measurements, which may miss clinically relevant glucose fluctuations. CGM provides continuous glucose measurements and may allow earlier detection of hyperglycemia and more timely glucose management.
This study is designed as a multicenter, non-inferiority randomized controlled trial comparing CGM-guided glucose management with standard POCT-guided glucose management in two stroke centers in the Netherlands. The primary objective is to determine whether CGM-guided glucose management is non-inferior to POCT-guided management in terms of percentage time spent in hyperglycemia (glucose >10 mmol/L) during the first 72 hours of hospitalization.
Researchers will compare CGM-guided glucose management to POCT-guided glucose management to evaluate whether CGM can be used as an alternative strategy to guide glucose control in hospitalized stroke patients.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive glucose monitoring using a continuous glucose monitoring (CGM) system (FreeStyle Libre 2). Glucose management during hospitalization is guided by CGM measurements and used for treatment decisions according to the hospital glucose management protocol.
Device: Continuous Glucose Monitoring
Participants receive standard glucose monitoring using intermittent point-of-care testing (POCT) with capillary finger-prick measurements. Glucose management during hospitalization follows the hospital glucose management protocol based on POCT values. A blinded continuous glucose monitoring sensor (FreeStyle Libre Pro iQ) is placed for data collection purposes only. CGM data are not available to the clinical team and are not used for treatment decisions.
Diagnostic Test: Point-of-Care Testing
Continuous glucose monitoring using the FreeStyle Libre systems (Abbott Diabetes Care) to measure interstitial glucose levels through a subcutaneous sensor that continuously records glucose concentrations during hospitalization.
Also known as: FreeStyle Libre 2, CGM
Intermittent glucose monitoring using point-of-care finger-prick capillary blood glucose measurements according to the hospital glucose management protocol.
Also known as: POCT
Time spent in hyperglycemia (>10 mmol/L)
Percentage of time during hospitalization with glucose levels above 10 mmol/L measured using continuous glucose monitoring.
Time frame: During the first 72 hours of hospitalization
Duration of hyperlgycemic episodes (>10 mmol/L)
Duration of hyperglycemic episodes (\>10 mmol/L) measured using continuous glucose monitoring.
Time frame: During the first 72 hours of hospitalization
Duration of hypoglycemic episodes (<3.9 mmol/L)
Duration of hypoglycemic episodes (\<3.9 mmol/L) measured using continuous glucose monitoring.
Time frame: During the first 72 hours of hospitalization
Time in normoglycemia (3.9-10.0 mmol/L)
Percentage of time with glucose levels between 3.9-10.0 mmol/L measured using continuous glucose monitoring.
Time frame: During the first 72 hours of hospitalization
Time in hypoglycemia (<3.9 mmol/L)
Percentage of time with glucose levels \<3.9 mmol/L measured using continuous glucose monitoring
Time frame: During the first 72 hours of hospitalization
In-hospital complications
Occurrence of in-hospital complications, including infection, symptomatic intracranial hemorrhage, and delirium during hospitalization.
Time frame: During the first 72 hours of hospitalization
Neurological recovery
Neurological recovery assessed by change in National Institutes of Health Stroke Scale (NIHSS) score (range 0-42, higher scores indicate more severe neurological deficit) from baseline to 24 hours post-EVT. Early neurological improvement is defined as a ≥4-point decrease in NIHSS score, and major neurological improvement as a ≥8-point decrease or NIHSS ≤1.
Time frame: Baseline to 24 hours post-EVT
Good functional outcome
Good functional outcome defined as a modified Rankin Scale (mRS) score ≤2 (range 0-6, lower scores indicate better functional outcome).
Time frame: 3 months post stroke
Health-related quality of life
Health-related quality of life measured using the PROMIS-10 Global Health questionnaire (range 10-50, higher scores indicate better health-related quality of life).
Time frame: 3 months post stroke
All-cause mortality
Time frame: 3 months post stroke
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for May 2028, 25 months after the start.
Of 573 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 25 months is below that.
Counting every sponsor, half of 654 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Isala